Publications by authors named "Poojabahen Gandhi"
Article Synopsis
- Exploiting TRAILR2 activation could improve cancer treatments, but past therapies faced issues like low effectiveness and liver damage.
- The new TR2/CDH3 BAB antibody targets both CDH3 and TRAILR2, enhancing apoptosis specifically in tumor cells expressing CDH3, showcasing effectiveness in various cancers and CRISPR-engineered models.
- In pancreatic cancer, where current treatments are lacking, TR2/CDH3 BAB shows promise, especially when used with other chemotherapy drugs, indicating potential for effective cancer therapy with a good safety profile.
The fetal liver is the site of a major expansion of the hematopoietic stem cell (HSC) pool and is also a privileged organ to study megakaryocyte progenitor differentiation. We identified in the mouse fetal liver at day 13.5 a discrete stromal cell population harboring a CD45TER119CD31CD51VCAM-1PDGFRα (VP) phenotype that lacked colony-forming unit fibroblast activity and harbored an hepatocyte progenitor signature.
View Article and Find Full Text PDF